Please login to the form below
Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
An estimated 3.9 billion people globally are currently at risk of dengue, a mosquito-borne viral disease
Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
More than ten million adults in the US alone over the age of 50 are estimated to have the condition
Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
An estimated one in 100 people globally are affected by the inflammatory skin disease
NHS urges people yet to receive their COVID-19 booster to come forward
Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster
Gilead’s Trodelvy approved by FDA for metastatic breast cancer
HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases
World Health Organization releases new road map for breast cancer
Nearly 80% of breast and cervical cancer deaths occur in low- and middle-income countries
Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
Endometrial cancer is the sixth most common cancer in women worldwide
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
Around 210,000 people worldwide are diagnosed with the disease each year
ICR calls for improved biomarker cancer tests to help personalise treatment
Each cancer has a unique pattern of biomarkers that can affect how effective treatments are
Q&A: Claire Gillis
PME interviews VMLY&Rx's CEO
-
Q&A: Sarah GordonPME interviews Virgo Health's head of health
-
Q&A: Amar UrhekarPME interviews Ashfield Health's Global President
-
EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery modelsEndometrial cancer is the fourth most common cancer affecting women in the UK, with around 9,700 new cases every year
-
World Cancer Day: encouraging men to put their health firstA three-year campaign, running from 2022 to 2024, focuses on ‘Closing the Care Gap’
-
AbbVie’s Rinvoq approved by MHRA for Crohn's diseaseOver 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms
-
Roche’s Polivy recommended by NICE for lymphoma therapyAround 5,500 people in England are diagnosed with the aggressive blood cancer each year
-
GSK’s Benlysta given orphan drug status by FDA for systemic sclerosisThe rare autoimmune disease affects two to ten people per million and has limited treatments
-
Kite and Arcellx close multiple myeloma collaboration agreementThis haematological malignancy is the third most common in Europe and the US and is incurable for most patients
-
Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitisThis makes Dupixent the first and only targeted medicine indicated for this condition
Latest appointments
-
SCIRIS appoints Isaac Batley as new CEOBatley’s healthcare communications agency was acquired by Cello in 2014
-
Research Partnership announces new CEO Gareth PhillipsPhillips was previously UK managing director and head of EMEA at Ipsos
-
Sorted Communications appoints Harry Loney and Lorna Walkden as communications managersBoth Loney and Walkden have over 35 years’ experience in marketing and communication
-
Onyx Health appoints Trevor Pill as new managing directorPrior to joining Onyx Health, Pill was marketing manager for Pharma Nord
-
Havas Health & You appoints Laura Mizrahi as chief creative officer of H4B ChelseaMizrahi joins the agency from her role as executive creative director at FCB Health NY
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
